UCB's Global Corporate Website

This section is intended for media and financial analysts

UCB Confirms Annual Zyrtec Sales In The US - Xyzal Sells More Than Zyrtec In Europe

Brussels, 19 January 2005 - Following Pfizer's quarterly earnings release, UCB confirms that Zyrtec strengthened its leadership position as the number one most prescribed branded antihistamine in the US in new prescriptions. The US sales of Zyrtec have reached $ 1,287 million over the 12 months ending December 31 st , 2004 and $ 349 million for the fourth quarter. This is an anticipated decline of 3% for the 4 th quarter of 2004 and of 4% for the whole year against the same period in 2003.

In Europe, UCB's total allergy franchise increased by 5% in 2004 thanks to the continued growth of Xyzal, which was launched in 2001. Xyzal now sells more than Zyrtec in Europe and the recent approval of Xyzal in Persistent Allergic Rhinitis (PER), the first and only medication approved for this indication should fuel continuous growth. Xyzal IMS 1 market share in value reached 21.4% in France and 21.1% in Germany, in November 2004, Xyzal's largest markets in Europe.

Asset Download

Stay up-to-date on the latest news and information from UCB